Select Language
Complement C5
Complement C5 Overview
| English Name | Complement C5 | Approved Drugs | 8 |
| Drugs in Clinical Trials | 20 | Target Synonym | C5a，Complement Component 5，ECLZB，Anaphylatoxin C5a Analog，C5a Anaphylatoxin，C5b，C5，Prepro-C5，CPAMD4，Complement C5，C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4，C5D |
| Highest Development Stage | Approved | ||
| English Name | Complement C5 |
| Target Synonym | C5a，Complement Component 5，ECLZB，Anaphylatoxin C5a Analog，C5a Anaphylatoxin，C5b，C5，Prepro-C5，CPAMD4，Complement C5，C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4，C5D |
| Approved Drugs | 8 |
| Drugs in Clinical Trials | 20 |
| Highest Development Stage | Approved |
Complement C5 Product List
- Product Category
Protein (11)Kits (1)
- Product Status
Launched (12)
- Species
Human (6)Mouse (1)Rat (2)Cynomolgus (2)Rabbit (1)
- Tag
His Tag (7)His Tag & Avi Tag (3)Fc Tag (1)- (1)
- Conjugate
Unconjugated (8)Biotin-labeled (3)- (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT CO5-H52Ha |  Human | HEK293 | Human Complement C5 Protein, His Tag, low endotoxin (MALS verified) |  |  |  |
HOT CO5-H82E9 | Human | HEK293 | Biotinylated Human Complement C5 Protein, His,Avitag™ (MALS verified) |  | | |
HOT CO5-M52H4 |  Mouse | HEK293 | Mouse Complement C5 Protein, His Tag |  | | |
HOT CO5-R52H5 |  Rat | HEK293 | Rat Complement C5 Protein, His Tag |  | | |
CEA-B241 | Human | - | Human Complement C5 ELISA Kit | |||
CO5-H5253 | Human | HEK293 | Human Complement C5 Protein, Fc Tag |  | | |
CO5-H52H7 | Human | HEK293 | Human Complement C5 (w917s) Protein, His Tag (MALS verified) |  | | |
CO5-H52Hx | Human | HEK293 | Human Complement C5 (R885H) Protein, His Tag |  | | |
CO5-C52Hx |  Cynomolgus | HEK293 | Cynomolgus Complement C5 Protein, His Tag (MALS verified) |  | | |
CO5-C82E3 | Cynomolgus | HEK293 | Biotinylated Cynomolgus Complement C5 Protein, His,Avitag™ (MALS verified) |  | | |
Total: 12
- 1
- 2
Complement C5 Background
Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.
Complement C5 Synonyms
Complement C5,C5,CPAMD4
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Eculizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Hemoglobinuria, Paroxysmal | Details | |
| Eculizumab biosimilar (IBC GENERIUM) | Phase 3 Clinical | Ibc Generium | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Details | |
| Eculizumab biosimilar (Biocad) | BCD-148 | Phase 3 Clinical | BIOCAD JSC | Hemoglobinuria, Paroxysmal | Details |
| Cemdisiran | ALN-CC5; AD-62643; ALN-62643; L96 | Phase 3 Clinical | Alnylam Pharmaceuticals Inc | Atypical Hemolytic Uremic Syndrome; Geographic Atrophy; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Macular Degeneration; Myasthenia Gravis; Myositis; Myositis, Inclusion Body | Details |
| Tesidolumab | NOV-4; LFG-316 | Phase 2 Clinical | Morphosys Ag, Novartis Pharma Ag | Geographic Atrophy; Hemoglobinuria, Paroxysmal; Macular Degeneration; Panuveitis; Rejection of renal transplantation; Uveitis, Intermediate; Uveitis, Posterior; Wet Macular Degeneration | Details |
| IM-101 | IM-101 | Phase 2 Clinical | ImmunAbs Inc | Autoimmune Diseases; Myasthenia Gravis | Details |
| ABBV-6628 | ABBV-6628 | Phase 2 Clinical | Abbvie Inc | Geographic Atrophy; Macular Degeneration | Details |
| OCUL-101 | OCUL101 | Phase 2 Clinical | Shenzhen Oukejian Biomedical Technology Co Ltd | Diabetic macular oedema; Geographic Atrophy; Macular Degeneration; Retinal Neovascularization | Details |
| KRIYA-825 | KRIYA-825; VV-14295 | Phase 2 Clinical | Kriya Therapeutics Inc | Geographic Atrophy | Details |
| LP-005 | LP-005; RX-001 | Phase 2 Clinical | Longbio Pharma (Suzhou) Co Ltd | Amyotrophic Lateral Sclerosis; C3 glomerulopathy; Carcinoma, Non-Small-Cell Lung; Complement-Mediated Diseases; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Myasthenia Gravis; Periodontal Diseases; Peripheral Nervous System Diseases; Thrombotic Microangiopathies | Details |
| Vensobafusp alfa | P014; KP-104 | Phase 2 Clinical | Kira Pharmaceuticals LLC | Glomerulonephritis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Erythematosus, Systemic; Thrombotic Microangiopathies | Details |
| Omoprubart | CAN-106 | Phase 2 Clinical | Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd | Genetic Diseases, Inborn; Hemoglobinuria, Paroxysmal | Details |
| ALXN-5500 | ALXN-5500 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Hemoglobinuria, Paroxysmal | Details |
| RLYB-116 | RLYB-116 | Phase 1 Clinical | Affibody Ab, Swedish Orphan Biovitrum (Sobi) | Autoimmune Diseases; Hematologic Diseases; Immune System Diseases; Inflammation | Details |
| SYH-2061 | SYH2061; SYH-2061 | Phase 1 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Complement-Mediated Diseases; Glomerulonephritis, IGA; Nephrosis | Details |
| NM3086 | NM3086; NM-3086 | Phase 1 Clinical | NovelMed Therapeutics Inc | Hemoglobinuria, Paroxysmal | Details |
| Eculizumab biosimilar (Turgut Ardika) | TUR03; TUR-03 | Phase 1 Clinical | Turgut Ardika Pty Ltd | Details | |
| EA-5 | EA-5; EA5 | Phase 1 Clinical | Shandong Lanyi Pharmaceutical Technology Co Ltd | Antiphospholipid Syndrome; Hemoglobinuria, Paroxysmal; Kidney Diseases; Myasthenia Gravis; Thrombotic Microangiopathies | Details |
| RBD-7007 | RBD-7007 | Phase 1 Clinical | Suzhou Ribo Life Science Co Ltd | Glomerulonephritis, IGA | Details |
| eculizumab biosimilar(Isu Abxis) | ISU-305 | Phase 1 Clinical | Isu Abxis Co Ltd | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Avacincaptad pegol sodium | ARC-1905; ARC-187 | Approved | Archemix Corp | Zimura, Izervay | United States | Macular Degeneration; Geographic Atrophy | Iveric Bio Inc, Astellas Pharma Inc | 2023-08-04 | Geographic Atrophy; Macular Degeneration; Polypoidal choroidal vasculopathy | Details |
| Zilucoplan Sodium | RA-101495-SC; RA-101495; ZLP-AI | Approved | Ra Pharmaceuticals Inc, Ucb Sa | ZILBRYSQ, Zilbrysq, 卓倍可 | Japan | Myasthenia Gravis | Ucb Japan Co Ltd | 2023-09-25 | Amyotrophic Lateral Sclerosis; Coronavirus Disease 2019 (COVID-19); Hemoglobinuria, Paroxysmal; Muscular Diseases; Myasthenia Gravis | Details |
| Crovalimab | RO-7112689/F01; SKY-59; RO711269; RO-711269; RG-6107; CH-7092230; RO-7092230; RO-7112689 | Approved | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | 派圣凯, Piasky | Mainland China | Hemoglobinuria, Paroxysmal | Roche Pharma (Schweiz) Ag, Roche (China) Holding Ltd, Genentech Inc | 2024-02-06 | Anemia, Sickle Cell; Antiphospholipid Syndrome; Atypical Hemolytic Uremic Syndrome; Guillain-Barre Syndrome; Hemoglobinuria, Paroxysmal | Details |
| Ravulizumab | ALXN-1810; ALXN-1210 | Approved | Alexion Pharmaceuticals Inc, Xencor Inc | Ultomiris, 伟立瑞 | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2018-12-21 | Acute Kidney Injury; Acute Lung Injury; Amyotrophic Lateral Sclerosis; Atypical Hemolytic Uremic Syndrome; Coronavirus Disease 2019 (COVID-19); Delayed Graft Function; Dermatomyositis; Glomerulonephritis, IGA; Heart Diseases; Hemoglobinuria, Paroxysmal; Immunoglobulin A Vasculitis Associated Nephritis; Kidney Diseases; Kidney Failure, Chronic; Lupus Nephritis; Myasthenia Gravis; Neuromyelitis Optica; Pneumonia, Viral; Purpura, Schoenlein-Henoch; Rejection of renal transplantation; Renal Insufficiency, Chronic; Respiratory Distress Syndrome, Adult; Thrombotic Microangiopathies | Details |
| Eculizumab | LEX-98; h-5G1.1; 5G1-1; HAL-1 | Approved | Alexion Pharmaceuticals Inc | Soliris, 舒立瑞 | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2007-03-16 | Anemia, Hemolytic, Autoimmune; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Asthma; Atypical Hemolytic Uremic Syndrome; Delayed Graft Function; Diabetes Mellitus; End Stage Liver Disease; Glomerulonephritis, Membranoproliferative; Guillain-Barre Syndrome; HELLP Syndrome; Hemoglobinuria, Paroxysmal; Infant, Newborn, Diseases; Kidney Failure, Chronic; Macular Degeneration; Myasthenia Gravis; Nasopharyngeal Carcinoma; Neuromyelitis Optica; Parturition; Pre-Eclampsia; Rejection of renal transplantation; Rejection of organ transplantation; Thrombocytopenia; Urea Cycle Disorders, Inborn; Vagus Nerve Diseases | Details |
| Pozelimab | REGN-3918 | Approved | Regeneron Pharmaceuticals Inc | VEOPOZ | United States | Protein-Losing Enteropathies | Regeneron Pharmaceuticals Inc | 2023-08-18 | Geographic Atrophy; Hemoglobinuria, Paroxysmal; Myasthenia Gravis; Protein-Losing Enteropathies | Details |
| Eculizumab biosimilar (Amgen) | ABP-959 | Approved | Amgen Inc | BKEMV | United States | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Amgen Inc | 2024-05-28 | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Details |
| Eculizumab biosimilar (Samsung Bioepis) | SB-12; AM004; AMT-904; SB12 | Approved | Samsung Bioepis Co Ltd | Epysqli, EPYSQLI | EU | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Samsung Bioepis Nl Bv | 2023-05-26 | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Details |
Product Reviews
1***32022-08-10
0People LikeI tried to express this product myself and it didn’t work, so I purchased ACRO’s products for antibody screening. The binding activity is very good and method establishment is also going very smoothly. There is also complete technical support available to help us solve any problems that arise during our experiments.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호